FDA Rejects Summit Therapeutics’ Ivonescimab Application for Lung Cancer Treatment
Summit Therapeutics said the FDA rejected its application for ivonescimab as a lung cancer treatment. Shares fell pre-bell.
Summit Therapeutics said the FDA rejected its application for ivonescimab as a lung cancer treatment. Shares fell pre-bell.